The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 ...

It is crucial to be aware of the risk factors and symptoms associated with AMD to detect and manage the condition early.

A recent study found home-monitoring tests as a potential solution to reduce the burden of neovascular age-related macular ...

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia GlobeNewswire May 06 ...

Mesogen Inc. out of The Woodlands, Texas, has developed a transplantable Retinal Pigmented Epithelium (RPE) patch to cure ...

Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...

Three at-home vision-monitoring tools failed to detect worsening neovascular age-related macular degeneration (AMD), a ...

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company ...

To provide opportunity for encouragement, Phoenix-based Associated Retina Consultants, in coordination with the International ...

At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related ...

Named PRIMA, the device may help those with advanced dry age-related macular degeneration get improvements in their eyesight. The company is in talks to also conduct trials in the United States.

Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were ...